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Abstract Increasing evidence suggests that Na+/Cl^-depen-
dent neurotransmitter transporters exist as homo-oligomeric
proteins. However, the functional implication of this oligomeri-
zation remains unclear. Here we demonstrate the engineering of
a Zn2+ binding site at the predicted dimeric interface of the
dopamine transporter (DAT) corresponding to the external
end of transmembrane segment 6. Upon binding to this site,
which involves a histidine inserted in position 310 (V310H)
and the endogenous Cys306 within the same DAT molecule,
Zn2+ potently inhibits [3H]dopamine uptake. These data provide
indirect evidence that conformational changes critical for the
translocation process may occur at the interface between two
transporter molecules in the oligomeric structure. 2 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The dopamine transporter (DAT) terminates dopaminergic
neurotransmission by mediating rapid reuptake of released
dopamine from the synaptic cleft [1,2]. Together with the
closely related transporters for norepinephrine (NET) and se-
rotonin (SERT) the transporter belongs to the large family of
Naþ/Cl3-dependent transporters that are characterized by the
presence of 12 putative transmembrane domains and intracel-
lular N- and C-termini [1^3]. The packing of the 12 helices is
poorly understood, and no high-resolution structural informa-
tion is currently available.
The quaternary structure of Naþ/Cl3-dependent neuro-
transmitter transporters also remains unknown. Interestingly,
an increasing amount of evidence suggests that Naþ/Cl3-de-
pendent neurotransmitter transport proteins form homo-oli-
gomeric structures although the functional signi¢cance has
not been clari¢ed. In the SERT, formation of oligomers was
supported biochemically by the ¢nding that SERTs tagged
with di¡erent epitopes can be co-immunoprecipitated [4].
The observation of £uorescence resonance energy transfer be-
tween di¡erent spectral variants of green £uorescence protein
(YFP and CFP) fused to the SERT have also provided evi-
dence for the existence of SERT oligomers in living cells [5].
In the DAT, we obtained data suggesting that transmembrane
segment (TM) 6 forms part of a homodimeric interface [6].
Most importantly, we found that a cysteine situated at the
extracellular end of TM 6 (Cys306) can be symmetrically
cross-linked between two DAT molecules either through for-
mation of a disul¢de bridge catalyzed by copper phenanthro-
line or by covalent cross-linking using a bifunctional cysteine-
reactive cross-linker [6].
In this study we have taken advantage of the strict geo-
metrical requirements for binding of the Zn2þ ion and at-
tempted to engineer Zn2þ binding sites at the predicted oligo-
meric interface of DAT at the extracellular end of TM 6 by
performing a series of sequential histidine substitutions. Spe-
ci¢cally, we wished to investigate whether structural con-
straints imposed by Zn2þ binding at the oligomeric interface
either within the same transporter molecule or between two
adjacent molecules could a¡ect transporter function.
2. Materials and methods
2.1. Site-directed mutagenesis
The cDNA encoding the human dopamine transporter (hDAT) was
kindly provided by Dr. Marc G. Caron (Duke University, Durham,
NC, USA). Mutant transporters were constructed by polymerase
chain reaction (PCR)-derived mutagenesis using Pfu polymerase ac-
cording to the manufacturer’s instructions (Stratagene, La Jolla, CA,
USA). The generated PCR fragments were digested with the appro-
priate enzymes, puri¢ed by agarose gel electrophoresis, and cloned
into the eukaryotic expression vector, pRc/CMV (Invitrogen, Carls-
bad, CA, USA), containing hDAT. All mutations were con¢rmed by
restriction enzyme mapping and DNA sequencing.
2.2. Cell culture and transfection
COS-7 cells were maintained as described and transiently trans-
fected by the calcium phosphate precipitation method [7,8].
2.3. [3H]Dopamine uptake experiments
Uptake assays were performed modi¢ed from Giros et al. [9] using
2,5,6-[3H]dopamine (6.5^60 Ci/mmol) (Amersham Pharmacia Bio-
tech). Transfected COS-7 cells were plated in either 96 well dishes
(0.25U105 cells/well), 24 well dishes (105 cells/well) or 12 well dishes
(2^3U105 cells/well) to achieve an uptake level of 5^10% of total
added [3H]dopamine. The uptake assays were carried out 2 days after
transfection. Prior to the experiment, the cells were washed once in
100/500 Wl of uptake bu¡er (25 mM HEPES, 130 mM NaCl, 5.4 mM
KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM L-ascorbic acid and
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5 mM D-glucose, pH 7.4). Unlabelled dopamine, RTI-55 and/or Zn2þ
as indicated was added to the cells in varying concentrations, and
uptake was initiated by addition of 10 nM [3H]dopamine in a ¢nal
volume of 100/500 Wl. After 10 min incubation at 37‡C, the cells were
washed twice with 100/500 Wl uptake bu¡er, lysed in 50/300 Wl SDS
and left 1 h at 37‡C. 96 well samples were retained in their well
whereas 24 and 12 well samples were transferred to 24 well counting
plates (Wallac, Turku, Finland). 600 Wl of Opti-phase Hi Safe 3 scin-
tillation £uid (Wallac) was added followed by counting of the plates
in a Wallac Tri-Lux L-scintillation counter (Wallac). Non-speci¢c up-
take was determined in the presence of 1 mM non-labeled dopamine
(Research Biochemicals International, Natick, MA, USA). All deter-
minations were performed in triplicate.
2.4. Cross-linking experiments
Cross-linking experiments were performed as described previously
[6].
2.5. Calculations
Uptake data were analyzed by non-linear regression analysis using
Prism 3.0 from GraphPad Software (San Diego, CA, USA).
3. Results
Zn2þ potently inhibits [3H]dopamine uptake in a biphasic
manner with a high a⁄nity component (IC50 = 0.49 WM) and a
low a⁄nity component (IC50s 1000 WM) in COS-7 cells tran-
siently expressing the wild type (WT) hDAT (Table 1 and
[10]). Whereas the low a⁄nity component most likely is due
to non-speci¢c toxic e¡ects of Zn2þ, the high a⁄nity compo-
nent is due to interaction of Zn2þ with an endogenous high
a⁄nity Zn2þ binding site consisting of three coordinating res-
idues, His193 in the second extracellular loop, His375 at the
top of TM 7 and Glu396 at the extracellular face of TM 8
[10,11]. By substituting His193 with lysine, which is present in
the corresponding position in the NET, the Zn2þ potency is
markedly reduced compared to hDAT WT (IC50, 130 WM,
Table 1, Fig. 2 and [10]). This mutant expresses similarly to
the WT and was chosen as background for our attempts to
engineer new Zn2þ binding sites at the predicted oligomeric
interface at the top of TM 6.
Single histidine substitutions were made of residues 305^312
(Fig. 1 and Table 1). Substitution of Leu305 (H193K^L305H)
resulted in a non-functional transporter with no detectable
[3H]dopamine uptake (Table 1). All other mutants were func-
tional with KM values for dopamine uptake ranging from 0.5
WM to 4 WM (Table 1). H193K^C306H, H193K^E307H,
H193K^A308H, H193K^S309H, and H193K^I312H dis-
played Vmax values that varied from 50% to 133% of that of
the WT (2900^8000 fmol/min/105 cells). The Vmax values for
H193K^V310H and H193K^W311H were reduced to 400 and
100 fmol/min/105 cells, respectively (Table 1). In parallel to
this observation, we were unable to detect speci¢c binding of
Fig. 1. Two-dimensional representation of hDAT. The three coordinating residues of the endogenous Zn2þ binding site of hDAT (His193,
His375 and Glu396) are highlighted (white letters in enlarged black circles) [10,11]. To generate arti¢cial Zn2þ binding sites in the region en-
compassing the external end of TM 6, His193 was mutated to lysine. The positions substituted with histidines at the extracellular end of TM 6
are indicated by black letters in enlarged white circles (residues 305^312).
Fig. 2. Evidence for Zn2þ binding between a histidine in position
310 and Cys306 at the external face of TM 6 in hDAT. The ¢gure
shows Zn2þ inhibition of [3H]dopamine uptake in COS-7 cells tran-
siently expressing hDAT-H193K^V310H (black squares), hDAT-
H193K^C306A^V310H (black triangles) or hDAT-H193K^C306H^
V310H (white circles). The Zn2þ inhibition curve for hDAT-H193K
is shown for comparison as a dotted line. Data are the meansT
S.E.M. of three to seven experiments performed in triplicate.
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[125I]RTI-55 in H193K^V310H and H193K^W311H whereas
speci¢c binding similar to the WT was observed in the other
mutants (data not shown). Importantly, due to a lower sensi-
tivity of the binding assay this could in fact be expected if the
reduced Vmax was due to lower expression of functional pro-
tein for these two mutants. The loss of [125I]RTI-55 binding
was not due to a decrease in a⁄nity for RTI-55 since muta-
tion of Val310 to histidine did not change the ability of RTI-
55 to inhibit [3H]dopamine uptake in both constructs (IC50 = 5
[3^6] nM in H193K (n=3) as compared to 2.1 [1.9^2.4] nM
(n=3) in H193K^V310H and 8 [6^12] nM in H193K-W311H
(n=2), means followed by the S.E.M. interval).
All mutants were tested for their sensitivity to Zn2þ in
[3H]dopamine uptake experiments. Only in one of the mutants
(H193K-V310H) we observed a marked increase in apparent
Zn2þ a⁄nity as re£ected in a decrease in IC50 value from 130
WM in H193K to 16 WM in H193K^V310H (Fig. 2 and Table
1). The IC50 values for Zn2þ remained s 90 WM in the other
mutants and thus similar to H193K. The apparent increase in
a⁄nity for Zn2þ in V310H suggests that a new Zn2þ binding
site had been established in the transporter. First, we excluded
the possibility that this new site involved any of the coordi-
nating residues of the endogenous site at the top of TM 7 and
8 (His375 and Glu396) since mutation of these in the back-
ground of H193K^V310H did not alter the Zn2þ sensitivity of
the transporter (data not shown). Next, we investigated the
possibility that the nearby Cys306 was involved (besides his-
tidines, only cysteines and acidic residues are capable of e⁄-
ciently coordinating Zn2þ [12]). As shown in Fig. 2 and Table
2, substituting Cys306 with an alanine markedly decreased the
potency of Zn2þ inhibition of [3H]dopamine uptake in
H193K^C306A^V310H. Accordingly, the increased Zn2þ sus-
ceptibility seen in hDAT-H193K^V310H is likely due to the
coordination of Zn2þ by at least Cys306 and His310 within
the same DAT molecule. Additional support for this hypoth-
esis was obtained by the observation that a histidine could
substitute for the cysteine in position 306 (hDAT-H193K^
C306H^V310H) with respect to Zn2þ inhibition of [3H]-
dopamine uptake (Table 2 and Fig. 2). Furthermore, remov-
ing the histidine in position 310 from H193K^C306H^V310H
resulting in H193K^C306H increased the IC50 for Zn2þ inhi-
bition of dopamine uptake from 16 WM to 190 WM (Tables 1
and 2 and Fig. 2).
The molecular mechanism underlying the inhibitory e¡ect
of Zn2þ H193K^V310H was investigated by performing satu-
ration [3H]dopamine uptake experiments in the presence and
absence of 10 WM Zn2þ. The experiments showed that Zn2þ
was acting as a non-competitive inhibitor of substrate uptake
in H193K^V310H, as the presence of 10 WM Zn2þ did not
change the KM value for [3H]dopamine uptake (KM =0.5 [0.3^
0.9] WM in the presence of 10 WM Zn2þ and 0.7 [0.4^1.0] WM
in the absence of Zn2þ, means of n=3 followed by the S.E.M.
interval) whereas the level of substrate transport was reduced
by more than 60% (Vmax = 200T 40 and Vmax = 530T 130 in
the presence and absence of 10 WM Zn2þ respectively, means
of n=3 followed by S.E.M.). In comparison, neither the KM
value for [3H]dopamine uptake nor the uptake level was af-
fected by 10 WM Zn2þ in the control mutant H193K (data not
shown).
Since Cys306 can be symmetrically cross-linked between
two DAT molecules [6], it is potentially possible that positions
310 also are in close proximity across the dimeric interface of
DAT. Accordingly, we carried out cross-linking studies in a
DAT construct containing the mutations C306A^V310C.
However, in this construct, under conditions that give robust
cross-linking of Cys306, we saw no evidence of cross-linking
of Cys310, either with copper phenanthroline or with a series
of di¡erent length bifunctional methanethiosulfonate reagents
(data not shown). Next we wished to test the possibility that
the interaction responsible for the Zn2þ binding site between
Table 1
Dopamine uptake characteristics for hDAT WT and mutants
hDAT mutant KM WM [S.E.M. interval] Vmax (fmol/min/105 cells) T S.E.M. n IC50 (Zn2þ) WM [S.E.M. interval] n
WT 3.0 [2.4^3.7] 6000T 1200 8 0.49 [0.46^0.52] 6
H193K 2.3 [1.7^3.1] 6500T 900 9 130 [110^140] 7
H193K-L305H N.D. N.D. 2 N.D.
H193K-C306H 4.0 [3^5] 8000T 600 5 190 [160^240] 4
H193K-E307H 2.6 [2.5^2.8] 7000T 100 5 370 [320^420] 4
H193K-A308H 4.0 [3^5] 6000T 100 5 140 [130^160] 4
H193K-S309H 2.35 [2.31^2.40] 7600T 200 5 90 [80^100] 4
H193K-V310H 0.8 [0.7^1.1] 400T 20 6 16 [10^24] 4
H193K-W311H 0.5 [0.3^0.6] 100T 10 3 320 [260^390] 2
H193K-I312H 0.6 [0.4^0.9] 2900T 1200 3 120 [90^160] 3
ND: not detectable. The KM and Vmax values for [3H]dopamine uptake were calculated from non-linear regression analysis of dopamine uptake
data. Zn2þ inhibition of [3H]dopamine uptake was ¢tted to either a two site or a one site model. When ¢tted to the two site model, only the
high a⁄nity binding site is noted. The IC50 values used in the estimation of KM were calculated from means of pIC50 values and the S.E.M. in-
terval from the pIC50 T S.E.M.
Table 2
Zn2þ inhibition of [3H]dopamine uptake in hDAT-H193K^V310H and control mutants
hDAT mutant IC50 (Zn2þ) WM [S.E.M. interval] n
H193K^V310H 16 [10^24] 4
H193K^C306A^V310H 70 [60^90] 3
H193K^C306H^V310H 6 [3^12] 3
H193K^C306H 190 [160^240] 4
The Zn2þ inhibition data of [3H]dopamine uptake was ¢tted to either a two site or a one site model. When ¢tted to the two site model, only
the high a⁄nity binding site is noted. The IC50 values used in the estimation of KM were calculated from means of pIC50 values and the
S.E.M. interval from the pIC50 T S.E.M.
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positions 306 and 310 occurs across the dimer interface be-
tween Cys306 in one DAT and His310 in a second DAT. To
do this, we attempted to cross-link between a Flag-tagged
DAT construct containing the wild-type Cys306 and Val310,
and a stably co-expressed Myc-tagged DAT construct with
C306A^V310C. After treatment with copper phenanthroline
and the bifunctional reagent bis-(2-methanethiosulfonato-
ethyl)amine hydrochloride we observed dimeric species of
the Flag-tagged construct resulting from the cross-linking of
Cys306 in two DATs as described previously [6], but failed to
observe any Myc-tagged DAT in an oligomeric species (data
not shown), indicating that Cys310 was not cross-linked to
itself (consistent with the results described above) or with
Cys306 in a second DAT molecule.
4. Discussion
A wide range of membrane proteins have been shown to
exist as oligomeric complexes, e.g. receptor tyrosine kinases,
voltage-dependent and ligand-gated ion channels as well as G
protein-coupled receptors [13,14]. It is currently being dis-
cussed to what degree Naþ-coupled transporters form oligo-
meric structures. For example, the Naþ-glucose transporter-1
(SGLT-1) is most likely not an oligomer as evidenced by
freeze-fracture electron microscopy [15]. In contrast, freeze-
fracture studies of the glutamate transporter EAAT-3 sug-
gested a putative pentameric structure of this transporter
[16]. Among the Naþ/Cl3-dependent neurotransmitter trans-
porters, evidence against oligomerization has only been ob-
tained for the glycine transporters (GLYT-1 and GLYT-2)
[17] whereas convincing evidence suggests the existence of
both DAT oligomers and SERT oligomers [4^6].
The functional importance of Naþ/Cl3-dependent neuro-
transmitter transporter oligomerization is not known. If the
oligomerization is important for the translocation process, it
can be envisaged that conformational changes critical for the
transport process occur at the dimeric interface and/or are
transmitted between the subunits coupling the transporter
subunits functionally together in the oligomeric complex. In
this context, it is interesting to note that the crystal structures
of the dimeric extracellular domain of a metabotropic gluta-
mate receptor in agonist-bound and unbound states revealed
disul¢de-linked homodimers whose ‘active’ and ‘resting’ con-
formations are modulated through the dimeric interface by a
packed K-helical structure [18]. The fact that we were unable
to show an e¡ect of Cys306 cross-linking [6] could argue
against a similar scenario in the DAT. On the other hand,
Cys306 may be situated in a £exible loop and accordingly
disul¢de formation between two adjacent Cys306 residues
may not impose a structural constraint su⁄cient to inhibit
conformational changes at the dimeric interface of the trans-
porter. This may nonetheless be possible closer to or in the
transmembrane region if the individual DAT molecules are
functionally linked to one another.
In this study we have attempted to address this question by
taking advantage of the strict geometrical requirements for
binding of the small Zn2þ ion that have been thoroughly
de¢ned from crystal structures of numerous Zn2þ binding
proteins [12]. Of particular importance for the present study,
these structures have unravelled that the distance between the
coordinating atom of the Zn2þ binding residue (i.e. a histi-
dine, cysteine, aspartate, or glutamate) and the Zn2þ ion aver-
ages 2.0 AV [12]. Two residues involved in coordination of the
same Zn2þ ion must therefore be situated in close spatial
proximity in the tertiary or quaternary structure of the pro-
tein. We have previously utilized this information to probe
tertiary structure relationships in the DAT. First, we identi¢ed
three coordinating residues in a naturally occurring Zn2þ
binding site and subsequently we were able to engineer a series
of ‘non-natural’ Zn2þ binding sites in the transporter
[10,11,19]. Upon binding to both the endogenous and the
engineered sites, Zn2þ potently and non-competitively inhib-
ited dopamine uptake [10,11,19]. Most likely, this occurred by
constraining conformational changes critical for the translo-
cation process [10,11,19].
To investigate whether structural constraints imposed by
Zn2þ binding at the oligomeric interface could a¡ect trans-
porter function we made a series of histidine substitutions at
the external end of TM 6 in the background of a mutant
(H193K) insensitive to Zn2þ in micromolar concentrations.
Our results suggested that Zn2þ could be coordinated between
a histidine inserted in position 310 (V310H) and the endoge-
nous Cys306. The selective ability of Cys306 and His310 posi-
tioned four residues apart to bind Zn2þ together with the
apparent inability of Zn2þ to bind when histidines were in-
serted in the i+1 (G307H), i+2 (A308H), i+3 (S309H) or i+5
(W311H) position relative to Cys306 underlines the strict
speci¢city of the Zn2þ interaction.
We recently showed that Cys306 can be symmetrically
cross-linked between two DAT molecules [6]. Nonetheless,
we ¢nd it most likely that Zn2þ is coordinated by His310
and Cys306 only in the same molecule of H193K^V310H.
Zn2þ binding sites involving only two coordinating residues
generally display an a⁄nity around 1035 M [19^21]. If both
Cys306 and His310 coordinated Zn2þ in two adjacent mole-
cules, a much higher a⁄nity would be expected (1038^1039)
[20^22]. Moreover, we were unable to cross-link a cysteine
inserted in position 310 between two DAT molecules, suggest-
ing that the side chains of the residues in position 310 may not
be as close in the quaternary structure as those in position 306
and accordingly that Zn2þ coordination between His310 in
two adjacent molecules is less likely. We were also unable to
obtain experimental support for the alternative possibility that
Zn2þ is being coordinated between Cys306 in one molecule
and His310 in the adjacent molecule. Co-expression of H193K
(containing Cys306) with H193K^C306A^V310H did not re-
sult in increased Zn2þ sensitivity in comparison to control as
would be expected if Zn2þ was coordinated between two DAT
molecules (data not shown). Moreover, as described in Sec-
tion 3, we observed no cross-linking between Cys306 in one
DAT and Cys310 in a di¡erentially epitope-tagged co-ex-
pressed DAT.
In summary, we have been able to engineer a Zn2þ binding
site at the external end of TM 6 corresponding to the pre-
dicted dimeric interface for the DAT. Binding of Zn2þ to this
site was found to markedly impair transporter function. This
underlines the functional importance of this region of the
transporter and provides indirect evidence that conformation-
al changes critical for the translocation process occur at the
oligomeric interface between two DAT molecules. It is there-
fore tempting to speculate that oligomerization may have a
direct functional role rather than being just a structural fea-
ture of putative importance for proper protein folding and
protein stability.
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